Application No. PCT/US03/17347 Amendment dated December 2, 2004 Preliminary Amendment

REMARKS

Applicants have attached an abstract on a separate sheet of paper as required by U.S. practice. Applicants have amended the specification for purposes of adding the priority information. Claims 23, 24, and 27 - 31 have been cancelled. Claims 4, 7, 8, 9, 12, 13, 14, 15, 18 - 22 and 25 have been amended to remove multiple dependencies. Claims 1 - 22 and 25 - 26 remain in the application. No new matter has been added. It is respectfully submitted that the present application is in condition for allowance. An early consideration and notice of allowance are earnestly solicited.

Respectfully submitted,

Date: Neemba 2 2004

Karen L. Prus

Attorney of Record, Reg. No 39,337

GlaxoSmithKline

Corporate Intellectual Property Five Moore Drive, PO Box 13398

Research Triangle Park, NC 27709-3398

Telephone: 919-483-2192

Fax: 919-483-7988